.png)
Download investor and scientific decks.
Financial results, pipeline milestones, and strategic outlook.
Overall survival endpoints from Phase III study in mCRPC.
New facilities in EU and APAC for RLT production.
Actinium-225 based therapy for solid tumors.
Comprehensive financial and operational review.
Mechanism of action and biodistribution studies.
At Ayutara Therapeutics, we are pioneering targeted radiotherapeutics that deliver precision treatment to cancer cells while minimizing damage to healthy tissue. Our presentations showcase cutting-edge research, clinical progress, and our commitment to transforming outcomes in oncology.
High-affinity ligands ensure radiation reaches only tumor cells.
Encouraging early data across multiple solid tumor indications.
Building scalable manufacturing to bring therapies worldwide.